uniQure N.V (QURE) - 32.63% Below 52-Week High: Buy or Wait?

Stock Details

uniQure N.V. (QURE), a prominent company in the healthcare sector within the biotechnology industry, is based in Netherlands and primarily trades on the NMS.Currently, the stock is trading at $48.17. Over the past 52 weeks, it has ranged between $8.73 and $71.50. This places the current price at 67.4% of its 52-week high and 451.8% above its 52-week low. Recent trading volume was recorded at 957,689. The 14-day Relative Strength Index (RSI) stands at 68.85, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $40.59 by 18.67%. Similarly, it is above its 200-day moving average of $27.74 by 73.65%. The MACD histogram is 0.40, indicating bullish momentum (MACD Line: 2.00, Signal Line: 1.60). There is currently 1 active alert set for QURE by users.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-16.25

Price to Book

10.40

EV/EBITDA

-17.03

EPS (TTM)

-$4.06

Price to Sales

180.62

Beta

0.94

Less volatile than market

Q:How is QURE valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is QURE's risk profile compared to the market?

With a beta of 0.94, uniQure N.V. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 10.40 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-872.23%

EBITDA

$-182,916,000

Return on Equity

-157.61%

Return on Assets

-15.72%

Revenue Growth (YoY)

11.00%

Q:How profitable and efficient is QURE's business model?

0 The operating margin of -872.23% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -157.61% and ROA at -15.72%, the company achieves moderate returns on invested capital.

Q:What are QURE's recent growth trends?

uniQure N.V.'s revenue grew by 11.00% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$3.4B

Revenue (TTM)

$18.67M

Revenue/Share (TTM)

$0.30

Shares Outstanding

69.37M

Book Value/Share

$4.67

Asset Type

EQUITY

Q:What is QURE's market capitalization and position?

uniQure N.V. has a market capitalization of $3.4B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 69.37M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does QURE's price compare to its book value?

uniQure N.V.'s book value per share is $4.67, while the current stock price is $48.17, resulting in a price-to-book (P/B) ratio of 10.31. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$69.78

44.86% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for QURE?

13 analysts cover QURE with 77% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $69.78 implies 44.9% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on QURE?

Current analyst recommendations:1 Strong Buy, 9 Buy, 3 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 15, 2026, 02:04 AM

Technical Indicators

RSI (14-day)

68.85

Neutral

50-Day Moving Average

$40.59

18.67% above MA-50

200-Day Moving Average

$27.74

73.65% above MA-200

MACD Line

2.00

MACD Signal

1.60

MACD Histogram

0.40

Bullish

Q:What does QURE's RSI value tell investors?

The RSI (Relative Strength Index) for QURE is currently 68.85, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

Q:How should traders interpret QURE's MACD and moving average crossovers?

MACD analysis shows the MACD line at 2.00 above the signal line at 1.60, with histogram at 0.40. This bullish crossover suggests upward momentum is building. The 50-day MA ($40.59) is above the 200-day MA ($27.74), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Aug 15, 2026, 01:20 AM

Condition	Threshold	Created At
Earnings Announcement	3 days	Jan 27, 2026, 04:18 PM

Condition

Threshold

Created At

Earnings Announcement

3 days

Jan 27, 2026, 04:18 PM

uniQure N.V. (QURE) Stock